Last updated on February 2019

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)


Brief description of study

The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.

Detailed Study Description

This study will have a main 24-week treatment period and a 28-week extension period of treatment.

Clinical Study Identifier: NCT03449147

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Ballenberger Freytag Wenisch Institut fuer klinische Forschung GmbH ( Site 1011)
Neu-Isenburg, Germany
  Connect »

Study Coordinator

Gemeinschaftspraxis Zentrum ( Site 1005)
Frankfurt, Germany
4.1miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.